Could an immunotherapy combo keep stomach cancer from coming back?
NCT ID NCT07263386
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study looks at whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) can help prevent stomach cancer from returning after surgery. It involves 460 adults with a specific type of advanced stomach cancer (PD-L1 positive, stage N3) who have had their tumor completely removed. Participants will be randomly assigned to receive either chemo alone or chemo plus sintilimab, and researchers will track how long they stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.